Please login to the form below
Audentes
This page shows the latest Audentes news and features for those working in and with pharma, biotech and healthcare.
Astellas to support development of Taysha’s AAV-based gene therapy programmes
$3bn acquisition of Audentes – now Astellas Gene Therapies, California – in January 2020.
Latest news
-
Audentes’ rare disease gene therapy programme delayed after third patient death
According to Audentes, preliminary findings show that the immediate cause of death of the third patient was gastrointestinal bleeding. ... Additionally, Audentes’ investigation into why these three patients developed progressive liver dysfunction is
-
Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal
Closely follows $3bn acquistion of gene therapy specialist Audentes. Japanese pharma company Astellas has inked a deal to buy out US-based biotech Xyphos, to bolster its immuno-oncology pipeline. ... This deal closely follows Astellas’ $3bn acquisition
-
Astellas makes gene therapy a core focus with $3bn Audentes buy
According to Audentes, the therapy achieved significant and sustained improvements in neuromuscular function at two doses tested, with significant improvements in respiratory function. ... Meanwhile, Audentes has several other candidates in development,
-
Vertex eyes Duchenne market with Exonics, CRISPR deals
officer of neuromuscular and liver disease gene therapy player Audentes Therapeutics, to lead the effort. ... year in a phase 1/2 trial – as well as Pfizer and Audentes.
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Other safety and manufacturing events such as three patient deaths in the high-dose arm of the Audentes’ ASPIRO trial and an FDA refusal to review the biologics licence application for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
